What is Dynavax Technologies?
Dynavax Technologies Corporation, established in 1996 and headquartered in Emeryville, California, is a clinical-stage immunotherapy firm dedicated to harnessing the body's immune system through toll-like receptor (TLR) stimulation. The company's pipeline includes product candidates targeting multiple cancer indications, a vaccine for hepatitis B prevention, and a disease-modifying therapy for asthma. Its focus on innate and adaptive immune responses positions it as a key player in novel therapeutic development.
How much funding has Dynavax Technologies raised?
Dynavax Technologies has raised a total of $293.9M across 5 funding rounds:
Stock Offering
$45M
Stock Offering
$20.1M
Stock Offering
$43.9M
Stock Offering
$85.9M
Debt
$99M
Stock Issuance/Offering (2004): $45M, investors not publicly disclosed
Stock Issuance/Offering (2010): $20.1M, investors not publicly disclosed
Stock Issuance/Offering (2010): $43.9M, investors not publicly disclosed
Stock Issuance/Offering (2013): $85.9M, investors not publicly disclosed
Debt (2021): $99M backed by Coalition for Epidemic Preparedness Innovations
Key Investors in Dynavax Technologies
Coalition for Epidemic Preparedness Innovations
The Coalition for Epidemic Preparedness Innovations (CEPI) is a global partnership focused on funding and coordinating the development of vaccines against emerging infectious diseases. Their investment in Dynavax likely aligns with their mission to prevent epidemics through vaccine advancement.
What's next for Dynavax Technologies?
The substantial enterprise-level funding and recent strategic investment indicate Dynavax Technologies is poised for significant operational expansion and the advancement of its clinical programs. This capital infusion is expected to accelerate the development and potential commercialization of its innovative immunotherapy candidates, particularly in oncology and infectious diseases. The company's strategic financial backing suggests a strong belief in its proprietary TLR technology and its potential to address unmet medical needs.
See full Dynavax Technologies company page
